Clinical aspects of melatonin intervention in Alzheimer's disease progression

Autores
Cardinali, Daniel Pedro; Furio, Analía M.; Brusco, Luis I.
Año de publicación
2010
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Fil: Cardinali, Daniel P. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Fisiología; Argentina
Fil: Furio, Analía M. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Fisiología; Argentina
Fil: Furio, Analía M. Universidad de Buenos Aires. Hospital de Clínicas José de San Martín; Argentina
Fil: Brusco, Luis I. Universidad de Buenos Aires. Hospital de Clínicas José de San Martín; Argentina
Abstract: Melatonin secretion decreases in Alzheimer´s disease (AD) and this decrease has been postulated as responsible for the circadian disorganization, decrease in sleep efficiency and impaired cognitive function seen in those patients. Half of severely ill AD patients develop chronobiological day‐night rhythm disturbances like an agitated behavior during the evening hours (so‐called “sundowning”). Melatonin replacement has been shown effective to treat sundowning and other sleep wake disorders in AD patients. The antioxidant, mitochondrial and antiamyloidogenic effects of melatonin indicate its potentiality to interfere with the onset of the disease. This is of particularly importance in mild cognitive impairment (MCI), an etiologically heterogeneous syndrome that precedes dementia. The aim of this manuscript was to assess published evidence of the efficacy of melatonin to treat AD and MCI patients. PubMed was searched using Entrez for articles including clinical trials and published up to 15 January 2010. Search terms were “Alzheimer” and “melatonin”. Full publications were obtained and references were checked for additional material where appropriate. Only clinical studies with empirical treatment data were reviewed. The analysis of published evidence made it possible to postulate melatonin as a useful ad‐on therapeutic tool in MCI. In the case of AD, larger randomized controlled trials are necessary to yield evidence of effectiveness (i.e. clinical and subjective relevance) before melatonin´s use can be advocated.
Fuente
Current Neuropharmacology. 2010, 8 (3)
Materia
MELATONINA
ENFERMEDAD DE ALZHEIMER
ENSAYO CLINICO
RITMO CIRCADIANO
PRUEBAS NEUROPSICOLOGICAS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
Repositorio Institucional (UCA)
Institución
Pontificia Universidad Católica Argentina
OAI Identificador
oai:ucacris:123456789/1625

id RIUCA_80e862755ab398074398fe4da289d3c6
oai_identifier_str oai:ucacris:123456789/1625
network_acronym_str RIUCA
repository_id_str 2585
network_name_str Repositorio Institucional (UCA)
spelling Clinical aspects of melatonin intervention in Alzheimer's disease progressionCardinali, Daniel PedroFurio, Analía M.Brusco, Luis I.MELATONINAENFERMEDAD DE ALZHEIMERENSAYO CLINICORITMO CIRCADIANOPRUEBAS NEUROPSICOLOGICASFil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; ArgentinaFil: Cardinali, Daniel P. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Fisiología; ArgentinaFil: Furio, Analía M. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Fisiología; ArgentinaFil: Furio, Analía M. Universidad de Buenos Aires. Hospital de Clínicas José de San Martín; ArgentinaFil: Brusco, Luis I. Universidad de Buenos Aires. Hospital de Clínicas José de San Martín; ArgentinaAbstract: Melatonin secretion decreases in Alzheimer´s disease (AD) and this decrease has been postulated as responsible for the circadian disorganization, decrease in sleep efficiency and impaired cognitive function seen in those patients. Half of severely ill AD patients develop chronobiological day‐night rhythm disturbances like an agitated behavior during the evening hours (so‐called “sundowning”). Melatonin replacement has been shown effective to treat sundowning and other sleep wake disorders in AD patients. The antioxidant, mitochondrial and antiamyloidogenic effects of melatonin indicate its potentiality to interfere with the onset of the disease. This is of particularly importance in mild cognitive impairment (MCI), an etiologically heterogeneous syndrome that precedes dementia. The aim of this manuscript was to assess published evidence of the efficacy of melatonin to treat AD and MCI patients. PubMed was searched using Entrez for articles including clinical trials and published up to 15 January 2010. Search terms were “Alzheimer” and “melatonin”. Full publications were obtained and references were checked for additional material where appropriate. Only clinical studies with empirical treatment data were reviewed. The analysis of published evidence made it possible to postulate melatonin as a useful ad‐on therapeutic tool in MCI. In the case of AD, larger randomized controlled trials are necessary to yield evidence of effectiveness (i.e. clinical and subjective relevance) before melatonin´s use can be advocated.Bentham Science Publishers2010info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://repositorio.uca.edu.ar/handle/123456789/16251570-159X (impreso)1875-6190 (online)10.2174/157015910792246209Cardinali, D. P., Furio, A. M., Brusco, L. I. Clinical aspects of melatonin intervention in Alzheimer's disease progression [en línea]. Current Neuropharmacology. 2010, 8 (3). doi:10.2174/157015910792246209. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1625Current Neuropharmacology. 2010, 8 (3)reponame:Repositorio Institucional (UCA)instname:Pontificia Universidad Católica Argentinaengenginfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/2025-07-03T10:55:19Zoai:ucacris:123456789/1625instacron:UCAInstitucionalhttps://repositorio.uca.edu.ar/Universidad privadaNo correspondehttps://repositorio.uca.edu.ar/oaiclaudia_fernandez@uca.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:25852025-07-03 10:55:20.006Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentinafalse
dc.title.none.fl_str_mv Clinical aspects of melatonin intervention in Alzheimer's disease progression
title Clinical aspects of melatonin intervention in Alzheimer's disease progression
spellingShingle Clinical aspects of melatonin intervention in Alzheimer's disease progression
Cardinali, Daniel Pedro
MELATONINA
ENFERMEDAD DE ALZHEIMER
ENSAYO CLINICO
RITMO CIRCADIANO
PRUEBAS NEUROPSICOLOGICAS
title_short Clinical aspects of melatonin intervention in Alzheimer's disease progression
title_full Clinical aspects of melatonin intervention in Alzheimer's disease progression
title_fullStr Clinical aspects of melatonin intervention in Alzheimer's disease progression
title_full_unstemmed Clinical aspects of melatonin intervention in Alzheimer's disease progression
title_sort Clinical aspects of melatonin intervention in Alzheimer's disease progression
dc.creator.none.fl_str_mv Cardinali, Daniel Pedro
Furio, Analía M.
Brusco, Luis I.
author Cardinali, Daniel Pedro
author_facet Cardinali, Daniel Pedro
Furio, Analía M.
Brusco, Luis I.
author_role author
author2 Furio, Analía M.
Brusco, Luis I.
author2_role author
author
dc.subject.none.fl_str_mv MELATONINA
ENFERMEDAD DE ALZHEIMER
ENSAYO CLINICO
RITMO CIRCADIANO
PRUEBAS NEUROPSICOLOGICAS
topic MELATONINA
ENFERMEDAD DE ALZHEIMER
ENSAYO CLINICO
RITMO CIRCADIANO
PRUEBAS NEUROPSICOLOGICAS
dc.description.none.fl_txt_mv Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Fil: Cardinali, Daniel P. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Fisiología; Argentina
Fil: Furio, Analía M. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Fisiología; Argentina
Fil: Furio, Analía M. Universidad de Buenos Aires. Hospital de Clínicas José de San Martín; Argentina
Fil: Brusco, Luis I. Universidad de Buenos Aires. Hospital de Clínicas José de San Martín; Argentina
Abstract: Melatonin secretion decreases in Alzheimer´s disease (AD) and this decrease has been postulated as responsible for the circadian disorganization, decrease in sleep efficiency and impaired cognitive function seen in those patients. Half of severely ill AD patients develop chronobiological day‐night rhythm disturbances like an agitated behavior during the evening hours (so‐called “sundowning”). Melatonin replacement has been shown effective to treat sundowning and other sleep wake disorders in AD patients. The antioxidant, mitochondrial and antiamyloidogenic effects of melatonin indicate its potentiality to interfere with the onset of the disease. This is of particularly importance in mild cognitive impairment (MCI), an etiologically heterogeneous syndrome that precedes dementia. The aim of this manuscript was to assess published evidence of the efficacy of melatonin to treat AD and MCI patients. PubMed was searched using Entrez for articles including clinical trials and published up to 15 January 2010. Search terms were “Alzheimer” and “melatonin”. Full publications were obtained and references were checked for additional material where appropriate. Only clinical studies with empirical treatment data were reviewed. The analysis of published evidence made it possible to postulate melatonin as a useful ad‐on therapeutic tool in MCI. In the case of AD, larger randomized controlled trials are necessary to yield evidence of effectiveness (i.e. clinical and subjective relevance) before melatonin´s use can be advocated.
description Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
publishDate 2010
dc.date.none.fl_str_mv 2010
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://repositorio.uca.edu.ar/handle/123456789/1625
1570-159X (impreso)
1875-6190 (online)
10.2174/157015910792246209
Cardinali, D. P., Furio, A. M., Brusco, L. I. Clinical aspects of melatonin intervention in Alzheimer's disease progression [en línea]. Current Neuropharmacology. 2010, 8 (3). doi:10.2174/157015910792246209. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1625
url https://repositorio.uca.edu.ar/handle/123456789/1625
identifier_str_mv 1570-159X (impreso)
1875-6190 (online)
10.2174/157015910792246209
Cardinali, D. P., Furio, A. M., Brusco, L. I. Clinical aspects of melatonin intervention in Alzheimer's disease progression [en línea]. Current Neuropharmacology. 2010, 8 (3). doi:10.2174/157015910792246209. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1625
dc.language.none.fl_str_mv eng
eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Bentham Science Publishers
publisher.none.fl_str_mv Bentham Science Publishers
dc.source.none.fl_str_mv Current Neuropharmacology. 2010, 8 (3)
reponame:Repositorio Institucional (UCA)
instname:Pontificia Universidad Católica Argentina
reponame_str Repositorio Institucional (UCA)
collection Repositorio Institucional (UCA)
instname_str Pontificia Universidad Católica Argentina
repository.name.fl_str_mv Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentina
repository.mail.fl_str_mv claudia_fernandez@uca.edu.ar
_version_ 1836638330562805760
score 13.13397